1.60

3.03% -0.05

After Hours: 1.60

Beyondspring Inc (BYSI)

Overview News Price History Option Chain Discussions Forecast

Beyondspring Inc stock is traded at $1.60, with a volume of 5,195. It is down -3.03% in the last 24 hours and up +17.65% over the past month. BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Previous Close:

$1.65

Open:

$1.61

24h Volume:

5,195

Relative Volume:

0.28

Market Cap:

$65.79M

Revenue:

$1.88M

Net Income/Loss:

$-8.48M

P/E Ratio:

-8.5061

EPS:

-0.1881

Net Cash Flow:

$-19.13M

1W Performance:

-6.98%

1M Performance:

+17.65%

6M Performance:

-19.19%

1Y Performance:

-46.67%

1-Day Range:

$1.60

$1.62

1-Week Range:

$1.56

$1.75

52-Week Range:

$1.175

$3.44

Beyondspring Inc Stock (BYSI) Company Profile

Name

Beyondspring Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

646-528-4184

Address

100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY

Employee

Twitter

@BeyondSpringInc

Next Earnings Date

2026-05-11

Latest SEC Filings

BYSI's Discussions on Twitter

Compare BYSI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BYSI Beyondspring Inc	1.60	67.85M	1.88M	-8.48M	-19.13M	-0.1881
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Beyondspring Inc Stock (BYSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-21	Downgrade	BofA Securities	Buy → Underperform
Dec-02-21	Downgrade	Jefferies	Buy → Hold
Dec-01-21	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-01-21	Downgrade	William Blair	Outperform → Mkt Perform
Sep-09-21	Initiated	Robert W. Baird	Outperform
Aug-04-21	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-05-21	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-21	Initiated	BofA Securities	Buy
Dec-29-20	Initiated	Evercore ISI	Outperform
Feb-07-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	Nomura	Buy
Dec-03-19	Initiated	William Blair	Outperform
Jul-10-19	Reiterated	H.C. Wainwright	Buy
Apr-30-19	Downgrade	Maxim Group	Buy → Hold
Oct-25-18	Reiterated	Maxim Group	Buy

View All

Beyondspring Inc Stock (BYSI) Latest News

Jun 14, 2026

BYSI Q1 2026 Earnings: Net Loss Narrows Amid Ongoing Clinical DevelopmentProfitability Analysis - newsline.com

Jun 14, 2026

Jun 13, 2026

BYSI Q1 2026 Earnings: Pipeline Progress Amidst Pre-Revenue PhaseNet Profit Margin - newsline.com

Jun 13, 2026

Jun 05, 2026

BeyondSpring Announces Major Leadership Transition and New CEO - The Globe and Mail

Jun 05, 2026

Jun 04, 2026

BeyondSpring names new CEO as founder transitions to chairman role - StreetInsider

Jun 04, 2026

BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition - citybiz

Jun 04, 2026

BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com - Investing.com South Africa

Jun 04, 2026

BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026 - marketscreener.com

Jun 04, 2026

BeyondSpring names new CEO, CFO as founder shifts to chairman role - Investing.com Nigeria

Jun 04, 2026

BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program - Stock Titan

Jun 04, 2026

BeyondSpring Inc. Announces Leadership Transition to Enhance Focus on DUBLIN-4 Program and Plinabulin Development - Quiver Quantitative

Jun 04, 2026

BeyondSpring reports phase 2 lung cancer trial results at ASCO By Investing.com - Investing.com Canada

Jun 02, 2026

Lung cancer trial tests drug trio after immunotherapy, 58% alive at 2 years - Stock Titan

Jun 02, 2026

May 29, 2026

BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% DeclineSynthetic Short - The Legal Advocate

May 29, 2026

BYSI Stock Chart | BEYONDSPRING INC (NASDAQ:BYSI) - ChartMill

May 29, 2026

May 27, 2026

BeyondSpring Q1 2026 Earnings: Narrowed Loss Per Share and Positive Stock MovementEarnings Decline Risk - The Legal Advocate

May 27, 2026

May 26, 2026

BeyondSpring (BYSI) Q1 2026 Earnings: Narrowing Loss and No Revenue as Clinical-Stage Biotech Advances PipelineProfit Recovery Report - The Legal Advocate

May 26, 2026

May 23, 2026

BYSI Q1 2026 Earnings: Narrow Loss and Modest Stock Gain as Pipeline Progress ContinuesInterim Report - The Legal Advocate

May 23, 2026

May 22, 2026

BeyondSpring Q1 2026 Earnings: Narrowing Loss Highlights Pipeline Progress Amid Zero RevenueTrending Buy Opportunities - Newser

May 22, 2026

May 18, 2026

BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative

May 18, 2026

Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan

May 18, 2026

BYSI BeyondSpring beats Q4 EPS estimates by 11 but shares drop 25 on zero revenueValue Pick - Newser

May 18, 2026

May 17, 2026

Number of shareholders of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView

May 17, 2026

May 15, 2026

Lan Huang trust gifts 260,582 BeyondSpring (BYSI) shares in Form 4 filing - Stock Titan

May 15, 2026

BeyondSpring (BYSI) insiders report 14.1% each; trust transfers disclosed - Stock Titan

May 15, 2026

May 14, 2026

BeyondSpring Reports Q1 2026 Financial Results: Plinabulin Pipeline Progress and SEED Therapeutics Clinical Update – Minichart - Minichart

May 14, 2026

May 13, 2026

BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 13, 2026

BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh - Stock Titan

May 13, 2026

BeyondSpring Releases Q1 2026 Financial Results - AlphaStreet

May 13, 2026

BeyondSpring (BYSI) Q1 2026 Results: EPS -$0.05, Revenue $0 -- H - GuruFocus

May 13, 2026

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) - Yahoo Finance

May 13, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

May 13, 2026

BeyondSpring stock gains 6% on narrower loss, pipeline progress By Investing.com - Investing.com South Africa

May 13, 2026

BeyondSpring stock gains 6% on narrower loss, pipeline progress - Investing.com

May 13, 2026